These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
49. [Management of vascular adverse events during tyrosine kinase inhibitors in patients with chronic myeloid leukemia]. Takaku T Rinsho Ketsueki; 2020; 61(9):1018-1027. PubMed ID: 33162495 [TBL] [Abstract][Full Text] [Related]
50. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Steinberg M Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072 [TBL] [Abstract][Full Text] [Related]
51. Real-world analysis of tyrosine kinase inhibitor treatment patterns among patients with chronic myeloid leukemia in the United States. Henk HJ; Woloj M; Shapiro M; Whiteley J Clin Ther; 2015 Jan; 37(1):124-33. PubMed ID: 25467191 [TBL] [Abstract][Full Text] [Related]
52. Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia. Roskoski R Pharmacol Res; 2022 Apr; 178():106156. PubMed ID: 35257901 [TBL] [Abstract][Full Text] [Related]
53. Validation of imatinib therapy failure score (IMTF) in chronic phase chronic myeloid leukemia in real life practice. Ielo C; Scalzulli E; Carmosino I; Pepe S; Bisegna ML; Martelli M; Breccia M Leuk Lymphoma; 2023 Dec; 64(14):2324-2326. PubMed ID: 37689986 [TBL] [Abstract][Full Text] [Related]
54. Initial treatment for patients with CML. Goldman JM Hematology Am Soc Hematol Educ Program; 2009; ():453-60. PubMed ID: 20008231 [TBL] [Abstract][Full Text] [Related]
55. A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years. Lang AS; Mounier M; Roques M; Chretien ML; Boulin M J Clin Pharm Ther; 2015 Aug; 40(4):391-7. PubMed ID: 25865674 [TBL] [Abstract][Full Text] [Related]
56. [What is the best treatment for chronic-phase CML?]. Sakaida E Rinsho Ketsueki; 2021; 62(8):1012-1023. PubMed ID: 34497187 [TBL] [Abstract][Full Text] [Related]
57. Second-line Dasatinib Therapy Improved Compliance and Deep Molecular Responses in Imatinib-intolerant Chronic Myeloid Leukemia Patients. Markovic U; Bulla A; Leotta S; Stella S; Consoli ML; TambĂ L; Conticello C; DI Raimondo F; Stagno F Anticancer Res; 2020 Sep; 40(9):5313-5317. PubMed ID: 32878823 [TBL] [Abstract][Full Text] [Related]
58. Successful treatment of follicular lymphoma with second-generation tyrosine kinase inhibitors administered for coexisting chronic myeloid leukemia. Fujiwara SI; Shirato Y; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Mashima K; Umino K; Minakata D; Nakano H; Morita K; Yamasaki R; Kawasaki Y; Sugimoto M; Ashizawa M; Yamamoto C; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y Int J Hematol; 2018 Jun; 107(6):712-715. PubMed ID: 29185155 [TBL] [Abstract][Full Text] [Related]
59. Response to Tyrosine Kinase Inhibitors in Real-World Patients With Chronic Myeloid Leukemia. Szeto AH; Bucci T; Deal A; Zhu A; Ahmad M; Cass AS; Sketch MR; Kemper R; Zeidner JF; Foster MC; Muluneh B; Crona DJ Ann Pharmacother; 2022 Jul; 56(7):753-763. PubMed ID: 34541881 [TBL] [Abstract][Full Text] [Related]
60. Systematic Review and Meta-Analysis of -New-Generation Tyrosine Kinase Inhibitors versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia. Pan P; Wang L; Wang Y; Shen L; Zheng P; Bi C; Zhang A; Lv Y; Xue Z; Sun M; Sun C; Li J; Jin L; Yao Y Acta Haematol; 2020; 143(3):204-216. PubMed ID: 31514197 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]